Using Neoantigen Peptide Vaccine/Neoantigen-based DC to Treat Advanced Malignant Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
In this study, we provide a personalized tumor neoantigen peptide vaccine/neoantigen-based DC
treatment to patients with advanced malignant solid tumors. We observe the post-treatment
tumor burden status, the immune response induced by immune preparations, and the prolongation
of patient survival time, aiming to evaluate the effectiveness and safety of the
neoantigen-based DC treatment.
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital of Nanchang University